康芝药业
(300086)
| 流通市值：19.84亿 | | | 总市值：20.48亿 |
| 流通股本：4.41亿 | | | 总股本：4.55亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 123,627,683.55 | 100,728,124.62 | 114,288,937.74 | 144,398,335.1 |
| 应收票据及应收账款 | 64,784,702.41 | 70,367,879.96 | 109,657,499.98 | 139,632,075.22 |
| 其中：应收票据 | 1,126,464.51 | 6,039,751.7 | 8,963,850.08 | 3,757,451 |
| 应收账款 | 63,658,237.9 | 64,328,128.26 | 100,693,649.9 | 135,874,624.22 |
| 预付款项 | 44,087,002.59 | 34,836,872.6 | 37,628,030.24 | 28,099,556.86 |
| 其他应收款合计 | 62,654,202.09 | 57,843,259.32 | 63,558,280.69 | 55,461,487.23 |
| 存货 | 221,412,440.31 | 245,218,653.79 | 240,869,461.17 | 236,429,321.6 |
| 其他流动资产 | 5,782,987.38 | 6,227,160.15 | 3,051,653.26 | 5,328,359.85 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 522,349,018.33 | 515,221,950.44 | 569,053,863.08 | 609,349,135.86 |
| 非流动资产: | | | | |
| 其他权益工具投资 | 5,299,820.44 | 5,299,820.44 | 5,299,820.44 | 5,299,820.44 |
| 投资性房地产 | 226,006,954.99 | 226,006,954.99 | 226,006,954.99 | 226,006,954.99 |
| 固定资产 | 832,888,959.16 | 847,815,886.03 | 859,232,174.99 | 841,698,140.87 |
| 在建工程 | 162,214,301.92 | 146,290,548.41 | 111,363,435.06 | 145,622,743.83 |
| 生产性生物资产 | 21,775 | 17,160 | - | - |
| 无形资产 | 155,466,227.78 | 157,844,563.42 | 158,055,386.55 | 160,328,309.72 |
| 开发支出 | 46,857,139.71 | 46,857,139.71 | 43,668,460.47 | 43,639,714.81 |
| 商誉 | 20,627,224.75 | 20,627,224.75 | 20,052,309.9 | 20,052,309.9 |
| 长期待摊费用 | 29,598,559.2 | 32,348,065.99 | 38,032,992.62 | 37,383,388.91 |
| 递延所得税资产 | 59,346,296.84 | 58,039,012.31 | 43,370,168.58 | 42,300,437.46 |
| 其他非流动资产 | 26,945,860.19 | 29,611,426.85 | 57,086,723.97 | 33,945,284.97 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,565,273,119.98 | 1,570,757,802.9 | 1,562,168,427.57 | 1,556,277,105.9 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,087,622,138.31 | 2,085,979,753.34 | 2,131,222,290.65 | 2,165,626,241.76 |
| 流动负债: | | | | |
| 短期借款 | 201,241,038.05 | 174,510,492.5 | 169,800,000 | 139,892,222.18 |
| 应付票据及应付账款 | 73,580,840.06 | 75,561,946.57 | 63,820,288.1 | 78,020,557.22 |
| 其中：应付票据 | 5,778,248.8 | 5,778,248.8 | - | - |
| 应付账款 | 67,802,591.26 | 69,783,697.77 | 63,820,288.1 | 78,020,557.22 |
| 预收款项 | 240,000 | 240,000 | 12,300 | 7,784 |
| 合同负债 | 11,163,045.82 | 25,434,579.68 | 14,422,622.67 | 10,788,945.47 |
| 应付职工薪酬 | 8,054,136.4 | 8,171,944.58 | 8,658,701.75 | 11,087,888.05 |
| 应交税费 | 15,948,349.78 | 9,853,049.01 | 24,812,226.02 | 32,203,920.07 |
| 其他应付款合计 | 73,574,376.78 | 74,724,057.54 | 70,180,049.61 | 70,435,365.15 |
| 一年内到期的非流动负债 | 90,440,000 | 75,940,000 | 37,620,000 | 36,768,556.33 |
| 其他流动负债 | 1,448,548.8 | 3,194,049.61 | 1,761,422.43 | 1,382,876.33 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 475,690,335.69 | 447,630,119.49 | 391,087,610.58 | 380,588,114.8 |
| 非流动负债: | | | | |
| 长期借款 | 246,059,027.78 | 267,059,027.78 | 322,045,263.89 | 324,978,367.78 |
| 递延收益 | 50,440,754.38 | 51,128,269.05 | 47,491,283.72 | 48,178,798.39 |
| 递延所得税负债 | 33,143,393.95 | 33,328,580.67 | 34,039,704.29 | 33,857,204.29 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 329,643,176.11 | 351,515,877.5 | 403,576,251.9 | 407,014,370.46 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 805,333,511.8 | 799,145,996.99 | 794,663,862.48 | 787,602,485.26 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 455,124,411 | 450,000,000 | 450,000,000 | 450,000,000 |
| 资本公积 | 859,943,390.87 | 847,079,083.66 | 842,360,546.79 | 836,491,796.79 |
| 其他综合收益 | 51,975,089.8 | 51,984,914.82 | 51,984,914.82 | 51,984,914.82 |
| 盈余公积 | 54,941,795.33 | 54,941,795.33 | 54,941,795.33 | 54,941,795.33 |
| 未分配利润 | -171,389,850.19 | -149,522,249.94 | -95,164,020.59 | -48,659,061.5 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,250,594,836.81 | 1,254,483,543.87 | 1,304,123,236.35 | 1,344,759,445.44 |
| 少数股东权益 | 31,693,789.7 | 32,350,212.48 | 32,435,191.82 | 33,264,311.06 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,282,288,626.51 | 1,286,833,756.35 | 1,336,558,428.17 | 1,378,023,756.5 |
| 负债和股东权益合计 | 2,087,622,138.31 | 2,085,979,753.34 | 2,131,222,290.65 | 2,165,626,241.76 |
| 公告日期 | 2024-10-30 | 2024-08-27 | 2024-04-29 | 2024-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |